靶向原发性血小板增多症与骨髓纤维化中突变钙网蛋白的新策略
所有MPN相关致病性CALR突变均因移码产生同一新抗原肽,该肽直接激活血小板生成素受体导致肿瘤细胞不受控增殖。当前MPN治疗主要控制血细胞计数,非疾病修饰且非克隆选择性;突变CALR新抗原不在正常生理中表达,是理想药物靶点。本文综述突变CALR结构与功能、两种最常见突变类型的差异、现有治疗格局的不足,以及单克隆抗体、双特异性抗体、癌症疫苗、嵌合抗原受体T细胞和抗体药物偶联物等克隆选择性靶向突变CALR的临床与临床前策略。
要点
- 所有MPN相关致病性CALR突变均因移码产生同一新抗原肽,直接激活血小板生成素受体。
- 当前MPN治疗主要控制血细胞计数,非疾病修饰且非克隆选择性。
- 突变CALR新抗原不在正常生理中表达,是理想药物靶点,多种克隆选择性策略正在临床与临床前开发中。
核心结论
- 突变CALR靶向治疗的持续发展有望为长期疾病控制带来有前景的新策略。
研究设计与样本
- 综述:总结突变CALR的结构与功能、两种最常见突变类型的差异、CALR突变MPN的当前治疗格局及靶向突变CALR的临床与临床前实验策略。
主要发现
- 所有MPN相关致病性CALR突变均因移码导致同一新抗原肽翻译,该新抗原直接激活血小板生成素受体,引起肿瘤细胞不受控增殖。
- 当前MPN治疗主要聚焦血细胞计数控制,且非疾病修饰、非克隆选择性。
- 突变CALR新抗原肽具有功能且在正常生理中不表达,是理想药物靶点。
- 正在综述的单克隆抗体、双特异性抗体、癌症疫苗、嵌合抗原受体T细胞和抗体药物偶联物等策略旨在以克隆选择性方式靶向MPN中的突变CALR。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The discovery of calreticulin (CALR) mutations in patients with myeloproliferative neoplasms (MPNs) has paved the way for the elucidation of a unique disease mechanism that is particularly well suited to targeting by biologics. All MPN-associated pathogenic CALR mutations are characterized by a frameshift, resulting in translation of the same neoantigen peptide. This neoantigen directly activates the thrombopoietin receptor, leading to uncontrolled neoplastic cell proliferation. Current therapeutic approaches for MPNs are focused primarily on blood count control. Furthermore, current approaches are neither disease modifying nor clonally selective. However, because the mutant CALR neoantigen peptide is functional and not expressed in normal physiology, it is an ideal drug target. Here, we review the structure and function of mutant CALR, including the subtle yet clinically and therapeutically relevant differences between the 2 most commonly occurring types of mutation. We also review the current therapeutic landscape for CALR-mutated MPNs, highlighting the areas in which current approaches are inadequate. Finally, we review ongoing clinical and preclinical experimental approaches for targeting mutant CALR in MPNs in a clonally selective manner using monoclonal antibodies, bispecific antibodies, cancer vaccination, chimeric antigen receptor T cells, and antibody-drug conjugates. Taken together, we expect that ongoing developments in mutant CALR-targeted therapeutics will lead to promising novel strategies for long-term disease control.
引用
- Salzman GS, Mullally A. Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis. Blood. 2026. PMID: 40857671. doi:10.1182/blood.2025028642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。